Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 20/20 | 0.67 |
| ▸ | NR1H2 | P55055 | 18/20 | 0.67 |
| ▸ | PPARD | Q03181 | 11/20 | 0.65 |
| ▸ | PPARA | Q07869 | 9/20 | 0.65 |
| ▸ | PPARG | P37231 | 7/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5953868 | 0.89 | NR1H3 (0.69) | NR1H3NR1H2PPARDPPARAPPARG | |
| SCHEMBL6371470 | 0.89 | NR1H3 (0.75) | NR1H3NR1H2PPARDPPARAPPARG | |
| SCHEMBL5954077 | 0.88 | NR1H3 (0.63) | NR1H3NR1H2PPARDPPARAPPARG | |
| SCHEMBL5953462 | 0.88 | NR1H3 (0.63) | NR1H3NR1H2PPARDPPARAPPARG | |
| SCHEMBL6175211 | 0.88 | NR1H3 (0.66) | NR1H3NR1H2PPARDPPARAPPARG | |
| SCHEMBL5820509 | 0.86 | NR1H3 (0.62) | NR1H3NR1H2PPARDPPARAPPARG | |
| SCHEMBL6349269 | 0.86 | NR1H3 (0.70) | NR1H3NR1H2PPARDPPARAPPARG | |
| SCHEMBL5953874 | 0.86 | NR1H3 (0.66) | NR1H3NR1H2PPARDPPARAPPARG | |
| SCHEMBL6799183 | 0.85 | NR1H3 (0.71) | NR1H3NR1H2PPARDPPARAPPARG | |
| SCHEMBL6419299 | 0.85 | NR1H3 (0.71) | NR1H3NR1H2PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014807-A1 | Therapeutic compounds for treating dyslipidemic conditions | ADAMS ALAN D (US) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014807-A1 | Therapeutic compounds for treating dyslipidemic conditions | NR1H2, NR1H3, SREBF1 | NR1H3 2/4885NR1H2 1/4885PPARD 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.